the arbutus biopharma corporation ( nafus ) is a large pharmacological drug product that has been developed in the past decade and has been able to improve the functional cure rate of chronic hepatitis b. we are excited to share our progress in advancing our strategy and we are eager to share more details as we progress in the development of our early stage human hepatitis b and coronavirus assets. we will now open the call for question and answer.